NCT01658241View on ClinicalTrials.gov

Panobinostat Biological Correlates Study

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 16, 2012

Primary Completion Date

March 18, 2015

Study Completion Date

March 18, 2015

Conditions
Nodal LymphomaLymphoma With Cutaneous InvolvementLymphoma in Leukemic PhaseMarrow Involvement With LymphomaMultiple Myeloma
Interventions
DRUG

panobinostat

40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle

Trial Locations (1)

3002

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT01658241 - Panobinostat Biological Correlates Study | Biotech Hunter | Biotech Hunter